- Home
- IPHA vs SGMT Comparison
IPHA vs SGMT Comparison
Compare IPHA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- SGMT
- Stock Information
- Founded
- IPHA 1999
- SGMT 2006
- Country
- IPHA France
- SGMT United States
- Employees
- IPHA N/A
- SGMT N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- SGMT
- Sector
- IPHA Health Care
- SGMT
- Exchange
- IPHA Nasdaq
- SGMT Nasdaq
- Market Cap
- IPHA 148.3M
- SGMT 159.0M
- IPO Year
- IPHA 2019
- SGMT 2023
- Fundamental
- Price
- IPHA $1.77
- SGMT $4.13
- Analyst Decision
- IPHA Strong Buy
- SGMT Buy
- Analyst Count
- IPHA 1
- SGMT 6
- Target Price
- IPHA $11.50
- SGMT $23.00
- AVG Volume (30 Days)
- IPHA 42.3K
- SGMT 1.2M
- Earning Date
- IPHA 09-12-2024
- SGMT 11-13-2024
- Dividend Yield
- IPHA N/A
- SGMT N/A
- EPS Growth
- IPHA N/A
- SGMT N/A
- EPS
- IPHA N/A
- SGMT N/A
- Revenue
- IPHA $36,202,722.00
- SGMT N/A
- Revenue This Year
- IPHA N/A
- SGMT N/A
- Revenue Next Year
- IPHA $101.65
- SGMT N/A
- P/E Ratio
- IPHA N/A
- SGMT N/A
- Revenue Growth
- IPHA N/A
- SGMT N/A
- 52 Week Low
- IPHA $1.29
- SGMT $2.39
- 52 Week High
- IPHA $3.51
- SGMT $18.90
- Technical
- Relative Strength Index (RSI)
- IPHA 46.55
- SGMT 41.82
- Support Level
- IPHA $1.65
- SGMT $4.06
- Resistance Level
- IPHA $1.87
- SGMT $7.38
- Average True Range (ATR)
- IPHA 0.12
- SGMT 0.63
- MACD
- IPHA -0.03
- SGMT -0.11
- Stochastic Oscillator
- IPHA 33.47
- SGMT 2.11
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).